Monday, March 2, 2015

Delay HCV Tx and Watch Patients Die

Delay HCV Tx and Watch Patients Die

Even successful treatment carries risk if it is delayed, model suggests.
by Michael Smith
North American Correspondent, MedPage Today

SEATTLE -- Delaying hepatitis C (HCV) treatment in patients who also have HIV increases the risk of liver complications and death even if the therapy is successful, a researcher said.

In a computer modeling study, treating a patient in METAVIR stage F3 disease instead of stage F2 increased the risk of liver-related death from 5% to 10%, according to Cindy Zahnd, a research assistant at the University of Bern in Switzerland

And if successful HCV treatment was delayed until stage F4, the risk of liver-related death rose to 25%, compared with therapy at stage F2, Zahnd said here at the 2015 Conference on Retroviruses and Opportunistic Infections.

Continue reading...

No comments:

Post a Comment